A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT03404115 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Reproxalap Ophthalmic Solution (0.1%)
DRUG: Vehicle Ophthalmic Solution

Sponsor

Aldeyra Therapeutics, Inc.